## CTSH: Cognizant Technology Solutions  - XLK: Technology

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 5.0% in mid entry zone (3.0-6.0%), top quartile (84th pct) cross-sectional ranking. Short-term MRS_5 (2.6%) confirms momentum alignment. Strong momentum (+3.0% 5-day acceleration). Outperforming sector by 5.4%. Caution: overbought RSI (82).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($80.43)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 2
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Novanta (Nasdaq: NOVT) to present at J.P. Morgan 44th healthcare conf.**
- Source: Stock Titan | 20251215T160852 | Neutral | Relevance: 63%
- Novanta Inc. (Nasdaq: NOVT) announced that its Chair & Chief Executive Officer, Matthijs Glastra, and Chief Financial Officer, Robert Buckley, are scheduled to present at the J.P. Morgan 44th Annual Healthcare Conference on Wednesday, January 14, 2026, in San Francisco, California. Novanta is a global supplier of core technology solutions for medical and advanced industrial original equipment manufacturers. The company's shares are traded on Nasdaq under the symbol “NOVT.”

**2. Infosys Sees Heavy Call Option Activity as Market Eyes December Expiry**
- Source: Markets Mojo | 20251213T220824 | Neutral | Relevance: 55%
- Infosys Ltd is experiencing significant call option trading with a strike price of ₹1,600 for the December 30, 2025 expiry, indicating bullish investor sentiment despite the stock's recent underperformance. This activity suggests market participants anticipate an upward movement beyond ₹1,600 or are hedging existing positions, amidst mixed technical signals and moderate investor participation. The heavy call option volume highlights the importance of this strike price as a key resistance or target point as the year-end expiry approaches.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | UBS | $82 | $78 | +5% |
| 2025-11-21 | William Blair | $0 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | UBS | main | Neutral |
| 2025-11-21 | William Blair | up | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 20 ($0.00M) |
| Sells | 14 ($1.22M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+0.8%)
- Blackrock Inc.: 10.5% (-0.2%)
- JPMORGAN CHASE & CO: 8.2% (+108.3%)
- State Street Corpora: 5.2% (-0.9%)
- Pzena Investment Man: 3.7% (+1.5%)

### Key Risks

1. Elevated short interest (8.1%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_10 improving +3.0% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.48 suggests fair value with growth premium. Forward P/E 15.0x stretched relative to 7% growth. Quality metrics strong (ROA 10%). Balance sheet: strong liquidity (2.4x), low leverage (D/E 0.35), $1.2B free cash flow. Analyst sentiment positive (1 raises, avg +5%). Insider selling cluster ($1.2M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $41.0B |
| Beta | 0.97 |
| 52W Range | $65.15 - $90.82 |
| Short Interest | 8.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.48 |
| Forward P/E | 15.0 |
| Current P/E | 16.0 |
| YoY Growth | 6.9% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 1.9% to 5.0% (+3.0% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (3.0-6.0%), cross-sectional ranking at 84th percentile. MRS_5 at 2.6% confirms short-term momentum alignment. Outperforming sector by 5.4pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 82, risk of mean reversion. OFD pattern: -DLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 4.96% (CS: 85) | Strong |
| RSI_14 | 81.6 | Overbought |
| MACD Histogram | 0.47 | Bullish |
| vs SMA20 | 1.076x | Above |
| vs SMA50 | 1.149x | Above |
| vs SMA200 | 1.127x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $84.05
- **Stop Loss:** $80.43 (4.3% risk)
- **Target:** $89.48 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 276
- **Position Value:** $23,197.80
- **Portfolio %:** 23.20%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-04 (Est: $1.32)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.30 | $1.39 | +6.7% |
| 2025Q2 | $1.26 | $1.31 | +4.0% |
| 2025Q1 | $1.20 | $1.23 | +2.5% |
| 2024Q4 | $1.13 | $1.21 | +7.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*